Managed Care Review Board™ Presents: Health Plan Best Practice Insights to Improve Outcomes for Non-Small Cell Lung Cancer

Learn About:

1. The cost-effectiveness of various treatment options for NSCLC
2. Current recommendations for screening of NSCLC
3. Social determinants of health related to NSCLC treatment

Expert Faculty Presenters:

Ryan Haumschild, PharmD, MS, MBA, CPEL Vice President of Pharmacy Emory Healthcare and Winship Cancer Institute Click here for biography Carl Gay, MD, PhD Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Click here for biography Adam Hoye-Simek, PharmD Director of Pharmacy Devoted Health Click here for biography Jeremy Wigginton, MD, MBA, FAAFP Chief Medical Officer Capital Blue Cross Click here for biography Ann Fish-Steagall, RN, BSN SVP Patient Services and Health Care Delivery LUNGevity Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
This webcast will help to inform managed care professionals about the latest clinical, economic, and policy insights in the management of non-small cell lung cancer (NSCLC). Participants will explore current screening and treatment guidelines, the value of biomarker-driven therapies, and the cost-effectiveness of emerging options such as immune checkpoint inhibitors and next-generation sequencing. The program also addresses real-world challenges including disparities in care, diagnostic delays, and coverage barriers. Through expert-led discussions and case examples, attendees will gain actionable strategies to align evidence-based treatment with value-based care, improve care coordination, and optimize outcomes for patients with NSCLC.

Educational Objectives
After completing this activity, the participant should be better able to:

• Outline current recommendations for screening of NSCLC and characterization of the disease at diagnosis to drive appropriate treatment selection
• Evaluate the cost-effectiveness of various treatment options for NSCLC to inform decision-making and optimize healthcare resource allocation
• Discuss relevant social determinants of health related to NSCLC treatment

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

This activity is certified as Knowledge-based CPE.

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

UAN: JA0003680-9999-25-193-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
Medical Education Resources designates this live activity for a maximum of 1.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.5 contact hours.

Disclosure of Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.